Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials is interpreted.